S. P. Ivanova
Research Subjects
S. P. Ivanova has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Dmitriy S. Kasatkin
Yaroslavl State Medical University
2 shared publications - A. A. Sokolova
Khanty-Mansiysk State Medical Academy; District Clinical Hospital
1 shared publication - A. G. Streknev
Saratov City Clinical Hospital No. 9
1 shared publication - A. I. Nilov
V.D. Seredavin Samara Regional Clinical Hospital
1 shared publication - Alexander I. Bezvodinskikh
Pavlov First Saint Petersburg State Medical University
1 shared publication - D.V. Lendoeva
Yaroslavl State Medical University, Yaroslavl, Russia
1 shared publication
Latest Publications
- Open Access
- 19 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 114-129
Experience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation
Introduction . Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP). Aim . To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP. Materials and methods . The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed. Results . Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety. Conclusions . The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.
- 19 April 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 114-129
Open AccessExperience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation
Introduction . Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP). Aim . To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP. Materials and methods . The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed. Results . Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety. Conclusions . The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (9) , 29-36
Approaches to vaccine prevention in multiple sclerosis
В статье представлен обзор современных представлений о вакцинопрофилактике при рассеянном склерозе (РС). У пациентов с РС в сравнении с общей популяцией повышен риск заболеваемости, склонность к более тяжелому течению, а также летальности от инфекций, которые можно предотвратить с помощью вакцин. В России до недавнего времени придерживались консервативной тактики ограничения вакцинопрофилактики у больных с аутоиммунными заболеваниями, в том числе с РС. Использование препаратов, изменяющих течение РС (ПИТРС), может влиять на восприимчивость к инфекциям и тяжесть их протекания. Скрининг на латентные инфекции, определение иммунного статуса, сбор анамнеза перенесенных инфекций и разработка на основе этих данных плана вакцинопрофилактики — важные части подготовки перед назначением ПИТРС с целью контроля возникновения или реактивации инфекций. Следует отдавать предпочтение применению инактивированных, субъединичных, конъюгированных вакцин, а также вакцин на основе анатоксинов. При разработке плана вакцинации по возможности избегать живых аттенуированных вакцин. На фоне приема ПИТРС первой линии ограничений к вакцинации нет. В случае вакцинации пациента с РС на фоне использования иммуносупрессантов, в том числе препаратов терапии иммунореконституции, необходимы индивидуальная оценка рисков и выбор времени проведения. Имеющиеся данные об осведомленности пациентов о вакцинопрофилактике существенно ограничены и требуют проведения массовых информационных мероприятий.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (9) , 29-36
Approaches to vaccine prevention in multiple sclerosis
В статье представлен обзор современных представлений о вакцинопрофилактике при рассеянном склерозе (РС). У пациентов с РС в сравнении с общей популяцией повышен риск заболеваемости, склонность к более тяжелому течению, а также летальности от инфекций, которые можно предотвратить с помощью вакцин. В России до недавнего времени придерживались консервативной тактики ограничения вакцинопрофилактики у больных с аутоиммунными заболеваниями, в том числе с РС. Использование препаратов, изменяющих течение РС (ПИТРС), может влиять на восприимчивость к инфекциям и тяжесть их протекания. Скрининг на латентные инфекции, определение иммунного статуса, сбор анамнеза перенесенных инфекций и разработка на основе этих данных плана вакцинопрофилактики — важные части подготовки перед назначением ПИТРС с целью контроля возникновения или реактивации инфекций. Следует отдавать предпочтение применению инактивированных, субъединичных, конъюгированных вакцин, а также вакцин на основе анатоксинов. При разработке плана вакцинации по возможности избегать живых аттенуированных вакцин. На фоне приема ПИТРС первой линии ограничений к вакцинации нет. В случае вакцинации пациента с РС на фоне использования иммуносупрессантов, в том числе препаратов терапии иммунореконституции, необходимы индивидуальная оценка рисков и выбор времени проведения. Имеющиеся данные об осведомленности пациентов о вакцинопрофилактике существенно ограничены и требуют проведения массовых информационных мероприятий.